Alex Knaster is Chairman and CEO of Pamplona Capital Management, an investment management firm he founded in 2004, with private equity, hedge fund and fund of funds operations. Alex has more than 25 years of experience in the investment banking
Michele Cleary joined The Mark Foundation as CEO in January 2017. Prior to that, she was Vice President of Clinical Translation Technologies & Operations at Bristol-Myers Squibb where she led biomarker research for cancer and other diseases.
Steven H. Bernstein, MD joined The Mark Foundation as its Chief Medical Officer in February 2018. He also serves as the Senior Vice President for Clinical Research and Development at Turnstone Biologics. Previously, Dr. Bernstein served as Chair, Immuno-Oncology Translational
Rebecca joined The Mark Foundation as Scientific Program Director in November 2017. She came to The Mark Foundation from D. E. Shaw Research, a firm engaged in scientific research and technological development in the field of computational biochemistry.
Maiya Guidry joined The Mark Foundation as Administrative Assistant in January 2018. Maiya comes to us with years of Administrative and Office support experience. Prior to joining the team, Maiya worked in the fashion industry as a Production Assistant at
Christa Justus joined The Mark Foundation as Chief Grants Management & Communications Officer in July 2017. She came to the Foundation directly from Gabrielle’s Angel Foundation for Cancer Research where she served as Director of Grants and Chief Content Officer.
Patrick Lewis joined The Mark Foundation as Head of Operations and Finance in May 2017. Prior to joining The Mark Foundation, Patrick was at Merck and Co., in diverse roles with increasing responsibility.
Rebecca Liu joined The Mark Foundation as Scientific Program Officer in October 2018. She came to the Foundation directly from March of Dimes where she served as Director of Research Programs managing biomedical research grants in the areas of development,
Ryan Schoenfeld joined The Mark Foundation as Senior Scientific Director in January 2018. Previously, he was Senior Director of Data Sciences at Janssen Pharmaceutical Companies of Johnson & Johnson, where he led a team of computational scientists delivering high impact
Dr. Levine is the Director of the Memorial Sloan Kettering Center for Hematologic Malignancies, Laurence Joseph Dineen Chair in Leukemia Research, Member of the Human Oncology and Pathogenesis Program, and Attending Physician at Memorial Sloan Kettering Cancer Center. Dr. Levine’s
Dr. Armstrong is Chairman of the Department of Pediatric Oncology at the Dana-Farber Cancer Institute, Associate Chief of the Division Hematology/Oncology at Boston Children’s Hospital, and the David G. Nathan Professor of Pediatrics at Harvard Medical School. He is also
Dr. Civin is Director of the Center for Stem Cell Biology and Regenerative Medicine at the University of Maryand School of Medicine, and also serves as Associate Dean for Research. Before coming to UMD, Dr. Civin held the King Fahd
Dr. Mardis is Co-Executive Director of the Institute for Genomic Medicine at Nationwide Children’s Hospital, and holds the Nationwide Foundation Endowed Chair in Genomic Medicine. She also teaches as a Professor of Pediatrics at the Ohio State University College of
Dr. Roose is Principal Investigator and Vice Chair of Anatomy at the University of California, San Francisco. He is also a co-founder of UCSF’s ImmunoX, and of Seal Biosciences, Inc., and runs an organoid disease to biology team in UCSF’s
Dr. Velculescu is Co-Director of Cancer Biology and Professor of Oncology and Pathology at the Johns Hopkins Kimmel Cancer Center, and is a co-founder of Personal Genome Diagnostics. Dr. Velculescu has made a number of important advances in genomics and
Dr. E. John Wherry is the Director of the Institute for Immunology and Professor of Microbiology at the University of Pennsylvania. Dr. Wherry's expertise focuses on T cell exhaustion in chronic infections and cancer.